Bontia Bio develops New Zealand pet treatments

Bontia Bio, a Wellington-based synthetic biology company, said it is developing nature-based treatments for animal health, with its first commercial product aimed at fleas and ticks in companion animals. A May 16 social-media post from Genius ReFi described the New Zealand startup as providing “non-toxic relief” from flea and tick infestation, but did not disclose any new funding, launch date or regulatory milestone. Bontia Bio’s own website says its first product will be an orally delivered medication for treatment and prevention of fleas and ticks in cats and dogs. Public material from the company and its backers shows the business has already raised seed funding and is targeting the U.S. pet-parasite market. ### What exactly is Bontia Bio building for pets? Bontia Bio says its initial focus is a family of compounds with potent activity against invertebrate pests and no associated mammalian toxicity, according to its website. The company says its first commercial product will be an orally delivered animal-health medication for treatment and prevention of fleas and ticks in companion animals. Wellington UniVentures, the commercialization arm linked to the research behind the company, says the product is intended for cats and dogs and is based on antiparasitic compounds found in nature. (geniusrefi.com) Genius ReFi’s May post framed the same effort as “bitey bugs” protection and described the treatment as non-toxic, but offered no additional product specifications. ### Where did the technology come from? (bontiabio.com) The Ferrier Research Institute at Te Herenga Waka Victoria University of Wellington is the source of the underlying technology, according to Bontia Bio’s website and Wellington UniVentures. The company says it uses a patented synthetic biology platform and biosynthetic pathway reconstruction to access compounds originally created for plant protection. Sprout Agritech said on March 26, 2025 that researchers at the Ferrier Research Institute had determined how to produce the target compounds in high quantities using microbial fermentation. (wellingtonuniventures.nz) RNZ reported in May 2025 that the technology allowed naturally occurring antiparasitic compounds used in flea and tick treatments to be replicated in commercially viable quantities. (bontiabio.com) ### Who is behind the company? Dr. Matt Nicholson is listed by Bontia Bio as co-founder, director and chief executive officer. Prof. Emily Parker is listed as co-founder, director and chief scientific officer. Wellington UniVentures’ 2024 impact report says Bontia Bio was founded by Parker and Nicholson, and that scientists Taylor Hibbard and Kelly Styles were recruited to help build the venture. The company’s website also lists Sprout Agritech chief executive Sandhya Sriram as a board member and Crispin Dye, an investment manager at Sprout Agritech, as a board observer. (sproutagritech.com) ### How much money has Bontia Bio raised? (bontiabio.com) Sprout Agritech said on March 26, 2025 that Bontia Bio had raised NZ$1.25 million in seed funding. Sprout said the round was led by Sprout Agritech, supported by Booster NZ’s Innovation Fund, and included a NZ$750,000 repayable grant from Callaghan Innovation. The May 16 Genius ReFi post did not announce a fresh round or provide any updated financing figure. (wellingtonuniventures.nz) Other public profiles, including NBR and Wellington UniVentures, also reference the NZ$1.25 million seed raise rather than a newer disclosed amount. ### Why is the U.S. market part of the plan? Sprout Agritech said Bontia Bio’s initial commercialization focus is the U.S. market, which it described as representing about half of the global pet anti-parasitic industry and operating under a single regulatory system. (sproutagritech.com) The investor said the company planned to seek U.S. Food and Drug Administration approval after initial successful testing in New Zealand and Australia. (nbr.co.nz) Bontia Bio’s website does not give a launch date or approval timetable. The site says only that the company is bringing to market products for animal health and crop protection using its synthetic biology platform. ### What comes next for the startup? Wellington UniVentures says Bontia Bio spun out in 2025 after completing its seed round and is using its methodology to bring a microbial-derived flea and tick treatment to market. The same UniVentures portfolio page says the company would seek further venture investment in the early part of 2026 to support its initial product and other animal-health and crop-production opportunities. (sproutagritech.com) (bontiabio.com) As of May 17, 2026, the most recent public materials tied to the company point to that fundraising plan, the previously disclosed NZ$1.25 million seed round, and continued development of the flea-and-tick program rather than a commercial launch date. (wellingtonuniventures.nz)